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Nalmefene is approved for as-needed pharmacological treatment in alcohol use disorder 
(AUD) by the European Medicines Agency. While the cellular effects of nalmefene have 
been thoroughly investigated, data are very limited on how this agent influences neural 
signals associated with inhibitory control and the visual analysis of environmental cues. 
This double-blind crossover study assessed the behavioral and neural effects of acute 
nalmefene administration in patients diagnosed with AUD. In experiment 1, we validated 
our experimental paradigm (electroencephalography combined with a modified Go/
NoGo task using images of alcoholic and nonalcoholic drinks as prime stimuli) in 20 
healthy adults to ensure that our protocol is suitable for assessing the behavioral and 
neural aspects of executive control. In experiment 2, we recruited 19 patients with AUD, 
and in a double-blind crossover design, we investigated the effects of nalmefene versus 
placebo on task performance (response accuracy, the sensitivity index, and reaction 
times), visual responses to appetitive cues (occipital P1, N1, and P2 components), 
and electrophysiological markers of conflict detection and response inhibition (frontal 
N2 and P3 waveforms). Under placebo, patients produced faster reaction times to 
alcohol-primed Go stimuli, an effect that was weak despite being statistically significant. 
However, the effect of alcoholic cues on the speed of response initiation disappeared after 
receiving nalmefene. We found no placebo versus nalmefene difference regarding our 
patients’ ability to accurately inhibit responses to NoGo stimuli or for occipital and frontal 
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INTRODUCTION
There is a considerable debate regarding nalmefene, an opioid 
agent, which has been approved by the European Medicines 
Agency (European Medicines Agency, 2013) as a treatment 
option in alcohol use disorder (AUD) (Gual et al., 2013). 
According to a meta-analysis, the drug is able to improve 
behavioral outcomes in patients with AUD (Mann et al., 2016), 
while others show that it has a limited efficacy in alcohol 
dependence therapy (Palpacuer et al., 2015; Soyka and Müller, 
2017), and rather, it is more useful as an as-needed, harm-
reducing pharmacotherapy (European Medicines Agency, 
2013; Aubin et al., 2015; Korpi et al., 2016). Furthermore, 
Foo et al. (2019) demonstrated recently in an animal model 
that the effectiveness of nalmefene is influenced by individual 
drinking profiles. This contradiction may root in a significant 
information gap regarding how molecular and system-wide 
properties of the drug are connected, e.g., what is nalmefene’s 
effect on cortical correlates of information processing.
The reinforcing mechanism of alcohol use is influenced by the 
interplay of opioid and dopaminergic systems (Spreckelmeyer 
et al., 2011). Alcohol modulates dopamine concentrations in 
the mesolimbic system in a dose-dependent manner, an effect 
that is mediated via opioid receptors, among other molecular 
mechanisms (Boileau et al., 2003; Martinez et al., 2005; Soyka 
et al., 2017). Through enhancing dopamine release, repeated 
alcohol consumption can alter reward prediction error signals 
in the midbrain and ventral striatum, which in turn will lead 
to maladaptive learning and to the development of rigid and 
habitual alcohol-consuming responses (Redish, 2004; Everitt and 
Robbins, 2005). The transition from goal-directed to habitual 
drug use is heavily influenced by the Pavlovian learning system 
that conditions the individual to environmental cues (e.g., 
the sight of one’s favorite pub) associated with reward, and 
facilitates response tendencies towards such stimuli, resulting 
in drug-seeking and drug-consuming behavior (Everitt and 
Robbins, 2005; Garbusow et al., 2014). By its direct effects on 
mu- and kappa opioid receptors, nalmefene probably decreases 
ethanol consumption by modulating dopamine transmission 
via GABAergic interneurons in the ventral striatum (Rose 
et al., 2016). Thus, via its effect on opioid and dopaminergic 
neurotransmission, nalmefene has a potential to reduce alcohol 
consumption by dampening the impact of Pavlovian responses 
on choice behavior, that is, by reducing the incentive salience of 
environmental cues.
In the systematic review of Pujol et al. (2018), the authors 
explored the cognitive effects of pharmacotherapy in addiction, 
but they pointed out the lack of clinical trials on the cognitive 
impact of nalmefene in patients with AUD. Only one study tried 
to fill this informational gap with investigating the behavioral 
and neural effects of nalmefene in 18 nontreatment seeking 
alcohol-dependent patients (Quelch et al., 2017). The authors 
found that nalmefene prolonged reaction times and reduced the 
amount of earned reward in a monetary reward anticipation task 
while keeping overall response accuracy unchanged. In addition, 
blood-oxygen-level-dependent signals assessed with functional 
magnetic resonance imaging were reduced following nalmefene 
treatment in the dorsal striatum, putamen, globus pallidus, 
brainstem, and the cerebellum. This result is in line with the above 
discussed molecular effects of nalmefene on the mesolimbic 
dopaminergic system. However, it remains unknown whether 
nalmefene also influences cortical mechanisms associated with 
cognitive control and decision making.
The answer to this question might have important therapeutic 
implications since behavioral choices and response inhibition 
were shown to be altered after acute alcohol intoxication 
(Fillmore et al., 2008) and in individuals with drinking problems 
(Ames et al., 2014) or AUD (Schad et al., 2019). Importantly, 
detoxified patients remaining abstinent during the follow-up 
period of 6 months demonstrated reduced responding to 
emotionally neutral stimuli embedded in an alcohol-related 
background, accompanied by increased hemodynamic responses 
in the right nucleus accumbens (Schad et al., 2019). These effects 
were absent in relapsers, indicating that stronger inhibitory 
control in the presence of alcoholic cues is related to the ability 
to maintain abstinence in AUD. However, Schad et al. (2019) 
did not find evidence for the involvement of any cortical area in 
cue-associated response inhibition, rendering the link between 
the prefrontal cortex and cognitive control over alcoholic cues in 
AUD speculative.
Utilization of event-related potentials (ERPs) paired with 
cognitive tasks is a frequently used method to investigate 
executive processes such as conflict detection, inhibitory control, 
and response selection (Kok et al., 2004). In the Go/NoGo task, 
subjects have to inhibit their responses when a rarely encountered 
NoGo stimulus is presented, whereas they have to make fast 
motor responses to frequently presented Go stimuli (Oddy and 
Barry, 2009; Hong et al., 2017). NoGo signals typically elicit two 
large ERPs above frontocentral scalp areas: the N2 is a negative 
waveform peaking between 200 and 300 ms after stimulus 
onset, while the subsequent P3 is a positive-going component 
arising 300–500 ms after stimulus presentation. The N2 has been 
primarily associated with conflict monitoring, whereas the P3 
was implicated in response inhibition (Huster et al., 2011; Luijten 
et al., 2014). These components reflect activity of a network 
consisting of several areas, including the dorsal anterior cingulate 
event-related potentials. Our results suggest that nalmefene might be potent in reducing 
the vigor to act upon alcoholic cues in AUD patients, but this effect is most probably 
mediated via subcortical (rather than cortical) neural circuits.
Keywords: nalmefene, alcohol use disorder, response inhibition, incentive salience, event-related potentials, 
Go/NoGo task
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cortex (dACC), basal ganglia, and the presupplementary motor 
cortex (Huster et al., 2010; Huster et al., 2011). Given that the N2/
P3 complex is a reliable neurophysiological marker of conflict 
detection and top–down inhibitory control, these waveforms can 
be used to evaluate whether nalmefene acts on executive process 
during a Go/NoGo task.
Heightened salience to alcohol- and other drug-related cues 
is related to attentional and emotional modulation of sensory 
processing (Volkow et al., 2008; Anderson, 2016). Early visual 
ERPs like the posterior P1, N1, and P2 components (peaking at 
90–110, 120–150, and 160–190 ms poststimulus, respectively) 
are enhanced in amplitude when attention is directed towards 
visual stimuli (Clark and Hillyard, 1996; Han et al., 2005) or 
when stimuli have strong emotional value (Vuilleumier, 2005). 
Thus, by assessing the effects of nalmefene on these waveforms 
during the presentation of alcoholic and nonalcoholic cues, 
we can investigate if this agent affects early sensory analysis of 
salient environmental stimuli.
In the current study, we aimed to assess how nalmefene 
influences sensory processing of appetitive cues and executive 
control related to response inhibition in alcohol-dependent 
patients. We used a modified Go/NoGo task in which emotionally 
neutral Go and NoGo stimuli were preceded by alcoholic and 
nonalcoholic cues, presented in the background. We chose this 
paradigm because it not only allows to investigate the effect of 
executive control over emotionally neutral visual stimuli but also 
to test the influence of appetitive contextual triggers on motor 
responses or the suppression thereof. In this respect, our task 
bears resemblance to Pavlovian-to-instrumental transfer (PIT) 
tasks that are sensitive to the interaction of instrumental and 
Pavlovian learning systems and hence can be used to assess value-
based learning mechanisms and decision-making strategies in 
psychiatric conditions such as AUD (Garbusow et al., 2014).
In experiment 1, we validated our experimental paradigm 
in a group of 20 healthy adults. This was done because, as the 
first experiment of this kind in our lab, we wanted to make sure 
that the well-documented Go versus NoGo effect on frontal 
N2 and P3 waveforms can be replicated with our modified, 
cue-primed protocol. Moreover, we also wanted to ensure that 
alcoholic cues do not alter behavioral and neural responses 
in healthy controls because we anticipated such effects to 
emerge in patients under placebo only. To match the design of 
experiment 2 as well as possible, we administered placebo pills 
to all participants in an open-label fashion. In experiment 2, 
we recruited short-term abstinent patients diagnosed with 
AUD, and in a double-blind crossover study, we evaluated the 
effects of nalmefene versus placebo on behavioral measures 
and ERP correlates of early visual processing and conflict 
monitoring/response inhibition.
Based on the established clinical efficacy of nalmefene, 
we expected that active treatment would improve inhibitory 
control in patients relative to placebo, manifesting in better 
response accuracy and higher sensitivity (d′) to refrain from 
responding to NoGo stimuli, especially when these stimuli are 
primed with images of alcoholic drinks. We also anticipated 
that patients receiving placebo would exhibit faster reaction 
times to alcohol-primed Go stimuli, indicative of enhanced 
response vigor to appetitive stimuli, and that this effect will 
be normalized following nalmefene administration. We 
hypothesized that, if the beneficial effect of nalmefene is 
due to more efficient top–down cognitive control, it would 
be associated with increased NoGo-associated frontal N2/
P3 amplitudes, pointing towards more efficient conflict 
detection/response inhibition after active treatment. 
Conversely, if nalmefene dampened the emotional salience 
of alcoholic cues during the course of early visual processing, 
we expected to observe reduced early visual ERPs elicited by 
alcoholic relative to nonalcoholic cues. Finally, we did not 
exclude the possibility that nalmefene would influence task 
performance only, without modulating any ERP component. 
This result would indicate that nalmefene primarily acts on 
subcortical structures such as the striatal region (Quelch 
et al., 2017), without robustly influencing frontal and occipital 
cortical processes in our task.
EXPERIMENT 1
Methods and Materials
Participants
We enrolled 20 healthy adults to validate our experimental 
paradigm (Table 1). Mental and neurological disorders 
TABLE 1 | Demographic and clinical characteristics of participants.
Characteristics Healthy group
(experiment 1)
Patients
(experiment 2)
Group size 20 19
Sex (female/male) 5/15 5/14
Age (years) 43.70 ± 6.61 48.32 ± 10.61
Education (levels 1/2/3) 0/12/8 3/9/7
Frequency of alcohol consumption 1. No alcohol consumption at all (N = 8)
2. Consumed alcohol consumption one to three occasions monthly (N = 9)
3. Consumed alcohol consumption once per week (N = 3)
Short-term 
abstinent group 
(<2 months)
Duration of problematic alcohol consumption (years) – 15.68 ± 11.87
Duration of lifetime abstinence (years) – 2.16 ± 2.81
Data are mean ± SD or N. Educational levels: 1, primary education or below; 2, secondary education (high school, vocational school); 3, postsecondary education (college, 
graduate school).
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and alcohol and drug dependence were exclusion criteria 
(based on self-report). With respect to the frequency of 
alcohol consumption, eight participants reported no alcohol 
consumption at all, nine consumed alcoholic drinks on one to 
three occasions monthly, and three consumed alcohol once per 
week. Participants received payment for participation (5,000 
Hungarian Forints corresponding to approximately 15 Euros). 
Every participant was informed about the study procedure, and 
they declared their agreement in a written consent. The study 
received certificate of ethical approval from Clinical Research 
Coordination Centre, University of Szeged (number of ethical 
approval: 171/2014).
Study Design and Task Description
Since we initially planned to compare the results from this 
group to those obtained from AUD patients after receiving 
either nalmefene or placebo, we asked control participants 
to take our placebo product (vitamin D3; dose, 25 μg) before 
the start of the data collection. Every participant was aware of 
receiving placebo in the experiment, which is one reason for 
why we did not compare data from the two groups eventually 
(see: “Limitations”). We used a special computerized Go/
NoGo task combined with electroencephalography (EEG) to 
assess the behavioral and neural correlates of the processing of 
alcoholic stimuli and their influence on executive control. The 
task consisted of stimuli depicting alcoholic drinks or alcohol-
free beverages as primes (Petit et al., 2012; Kreusch et al., 2014, 
Figure 1). Participants were sitting in a dark room, in front of 
a 19″ cathode ray tube monitor with a viewing distance of 80 
cm. Stimuli were presented, and responses were recorded with 
E-prime 2.0 Professional program (Psychology Software Tools, 
Inc., Sharpsburg, Pennsylvania, USA). During the task, 50% of 
the participants had to press the space bar when they saw one 
letter (targets: W or M) appearing in the middle of the prime 
picture (Go stimulus) and had to inhibit responding for the other 
letter (NoGo stimulus). Stimuli were counterbalanced across 
patients. Participants had to accomplish the task as fast and 
accurate as possible. At the beginning of a trial, alcoholic and 
neutral prime pictures were shown for 1,000 ms, followed by a 
target stimulus, presented for 100 ms. An additional 1,000 ms was 
available for responding, and the trial ended earlier if a response 
was given. Trials were separated by a screen containing a white 
fixation cross (presented for a random period between 400 and 
600 ms) (Figure 1). The test contained 600 stimuli divided into 
10 blocks, separated by short breaks. Primes either depicted one 
of the five types of alcoholic (beer, wine, vodka, fruit brandy, and 
FIGURE 1 | Overview of our behavioral task. (A) Trial sequence in the Go/NoGo paradigm, with pictures of either (B) alcoholic drinks (beer, wine, vodka, fruit brandy, 
and liqueur) or (C) nonalcoholic beverages (mineral water, apple juice, tea, coffee, raspberry syrup) as prime stimuli. Please note that colored stimuli were used in 
both experiments. The blurred effect on the images was applied only in the publication.
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liqueur) or nonalcoholic (water, apple juice, tea, coffee, raspberry 
syrup) drinks. Since our primes were asymmetric stimuli (Figure 
1), every image was presented either in its original or mirrored 
version in 50–50% of trials. The experiment began with a short 
practice block consisting of 20 stimuli. Each block contained 60 
trials, with 20 alcohol-primed Go stimuli, 20 nonalcohol-primed 
Go stimuli, 10 alcohol-primed NoGo stimuli, and 10 nonalcohol-
primed NoGo stimuli, presented in a random order. The whole 
procedure lasted for 30–40 min.
EEG Recording and Analysis
EEG was collected with a 32-channel Biosemi EEG System 
(BioSemi B.V., Amsterdam, The Netherlands). Sampling rate 
was set to 1,024 Hz; no frequency filters were used during 
data collection. Ag/AgCl electrodes were attached to an elastic 
EEG cap, with electrodes positioned in accordance with the 
International 10-20 System (Jasper, 1958). Recording sites were 
Fp1, Fp2, F3, F4, F7, F8, Fz, FC1, FC2, FC5, FC6, C3, C4, Cz, 
T7, T8, CP1, CP2, CP5, CP6, P3, P4, P7, P8, Pz, O1, O2, Iz, TP9, 
and TP10. The reference and ground electrodes (common mode 
sense and driven right leg electrodes in the active two system; 
Metting van Rijn et al., 1990) were placed in close proximity to 
the Cz position.
The data were analyzed with the Brain Vision Analyzer 2.0.3 
software (Brain Products GmbH, Gilching, Germany). Data 
were re-referenced to common average and filtered with 0.5 Hz 
high-pass zero phase-shift Butterworth filter (24 dB/oct). Ocular 
artifacts were removed using an algorithm described by Gratton, 
Coles, and Donchin (Gratton et al., 1983). Continuous EEG 
was segmented to epochs from 100 ms prestimulus to 600 ms 
poststimulus and baseline corrected from −100 to 0 ms. Artifact 
rejection was conducted semiautomatically, so epochs were 
visually also inspected for horizontal eye movement- or muscle 
activation-related artifacts. After averaging, data were filtered 
with a 30-Hz (occipital responses to prime stimuli) or 15-Hz 
(frontal ERPs evoked by Go/NoGo stimuli) low-pass zero phase-
shift Butterworth filter (24 dB/oct).
Visual P1, N1, and P2 ERPs were analyzed at the pooled 
occipital O1/O2 channels. Mean amplitudes of each component 
were measured in a 40-ms time window, centered around 
the group-averaged peak of waveforms collapsed across all 
experimental conditions (P1: 120 ms; N1: 180 ms; P2: 260 
ms). The frontal N2 was measured at electrode Fz, whereas 
the subsequent P3 was quantified at electrode Cz because of its 
more central scalp distribution. Mean N2 and P3 amplitudes 
were extracted from a 40-ms time window centered at 290 and 
420 ms, respectively.
Statistical Analysis
All statistical analyses were performed with SPSS for Windows, 
Version 22.0 (IBM SPSS Statistics, Armonk, New York State, 
USA). Accuracy was determined as the proportion of correct 
responses to each trial type (alcoholic vs. nonalcoholic primes; 
Go vs. NoGo stimuli). We used hit rates (proportion of correct 
responses to Go stimuli) and false alarms (proportion of motor 
responses to NoGo stimuli) from alcohol- and nonalcohol-
primed trials to calculate the sensitivity index (d′) from signal 
detection theory. This was done using the following formula: 
d′ = Zhit rate − Zfalse alarm rate, where Z is the inverse of the normal 
distribution function (Macmillan and Creelman, 2004). This 
parameter represents the individual’s efficacy of decision 
making (with higher values corresponding to more accurate 
responding) and has been widely used in Go/NoGo tasks in 
studies involving AUD patients (Saunders et al., 2008; Ames et 
al., 2014). In addition, we calculated median reaction times (RTs) 
for Go stimuli, separately for both priming conditions. Owing to 
near-ceiling effects in terms of response accuracy, we could not 
analyze RTs for incorrect responses to NoGo stimuli. Behavioral 
outcomes were analyzed with nonparametric tests because the 
assumption of normality was violated for all measures (Shapiro–
Wilk test, accuracy: p < 0.001; d′: p = 0.047; RT: p = 0.008). In the 
case of response accuracy, variation across the four trial types 
were assessed using Friedman test, with Wilcoxon signed-rank 
tests for follow-up pairwise comparisons using Bonferroni-
adjusted alpha levels of 0.0125. For d′ and RT, potential 
differences in performance between trials with alcoholic versus 
nonalcoholic primes were assessed with Wilcoxon signed-rank 
tests at an alpha level of 0.05.
Mean ERP amplitudes were analyzed with repeated-measures 
analysis of variance (ANOVA) with target (Go or NoGo; for 
frontal ERPs only) and prime (alcoholic or nonalcoholic; for 
occipital and frontal ERPs) as within-subject factors. Tests with 
p < 0.05 were considered as significant. Significant interactions 
were further evaluated with Bonferroni-corrected post-hoc tests. 
In order to demonstrate the magnitude of the observed effects, 
partial eta-squared (ηp2) values are also shown.
Results
Behavioral Measures
We found a significant variation in response accuracy across trial 
types [χ2(3) = 35.77; p < 0.001]. Follow-up pairwise comparisons 
revealed no effect of prime (Go: Z = −0.33, p = 0.739; NoGo: 
Z = −1.64, p = 0.100), but significant differences between 
performance for Go versus NoGo trials (alcoholic primes: Z = 
−3.71, p < 0.001; nonalcoholic primes: Z = −3.30, p = 0.001; Table 
2), with more accurate responding to Go stimuli. Neither d′ nor 
RT was significantly affected by prime type (d′: Z = −0.69, p = 
0.490, Figure 2A; RT: Z = −0.72, p = 0.468, Figure 2B). Overall, 
these results indicate that images depicting alcoholic beverages 
did not interfere with executive control in our healthy group.
Event-Related Potentials
Occipital P1, N1, and P2 amplitudes
For the P1 and N1 amplitudes, we found no significant main 
effects of prime [P1: F(1, 19) = 1.33, p = 0.262, ηp2 = 0.066; N1: 
F(1, 19) = 0.05, p = 0.811, ηp2 = 0.003; Figure 3A]. However, the 
P2 component was significantly larger for nonalcoholic primes 
[F(1, 19) = 48.84, p < 0.001, ηp2 = 0.720; Figure 3A].
Frontal N2 and P3 amplitudes
We found larger N2 amplitudes in NoGo relative to Go trials 
[F(1, 19) = 16.23, p = 0.001, ηp2 = 0.461; Figure 3B]. Neither the 
main effect of prime [F(1, 19) = 0.03, p = 0.858, ηp2 = 0.002], nor 
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the target × prime interaction was significant [F(1, 19) = 0.002, 
p = 0.967, ηp2 < 0.001]. Similar effects were observed for the P3 
component, with larger amplitudes for NoGo stimuli [F(1, 19) = 
72.30, p < 0.001, ηp2 = 0.792; Figure 3B] but no main effect of 
prime [F(1, 19) = 0.33, p = 0.571, ηp2 = 0.017] or target × prime 
interaction [F(1, 19) = 0.005, p = 0.946, ηp2 < 0.001]. These 
findings support behavioral results of the absence of prime-
associated effects on neural correlates of conflict detection and 
response inhibition in the control group.
EXPERIMENT 2
Methods and Materials
Participants
We enrolled 20 short-term (< 2 months) abstinent patients 
diagnosed with AUD (World Health Organization, 1992) at 
the Department of Psychiatry, University of Szeged, Hungary. 
Main demographical characteristics, alcohol consumption, 
and abstinence history of all patients are presented in Table 1. 
Comorbid mental and neurological disorders (verified by 
anamnestic documentation) and acute withdrawal symptoms 
were exclusion criteria. All patients were tested with the 
Hungarian version of the Wechsler Adult Intelligence Scale 
(Rózsa et al., 2010a; Rózsa et al., 2010b) to screen for extreme 
low IQ. We excluded one patient because his IQ score was in 
the zone of mental retardation (full-scale intelligence quotient = 
60), whereas scores for other patients were in the normal range 
(M = 94.26, SD = 17.29, minimum = 70, maximum = 125). 
Thus, data from 19 patients were included in the final analysis. 
Our study received certificate of ethical approval from Clinical 
Research Coordination Centre, University of Szeged (number 
of ethical approval: 171/2014). Every participant was informed 
about the study procedure and about possible adverse reactions 
of nalmefene, and they declared their agreement by signing the 
informed consent form.
Study Design and Task Description
In a double-blind, placebo-controlled crossover study design, we 
administered either placebo (vitamin D3, 25 μg) or nalmefene 
(18 mg) orally, in forms of identical white and tasteless pills 
of oval shape. We decided to investigate the effects of a single 
dose of nalmefene because this agent is recommended to be 
administered in a single dose on days when patients perceive a 
TABLE 2 | Behavioral accuracy (proportion of correct responses) in the four trial types from both experiments (mean ± standard deviations).
Alcoholic primes Nonalcoholic primes
Go trials
(hit rates)
NoGo trials
(1—false alarm rates)
Go trials
(hit rates)
NoGo trials
(1—false alarm 
rates)
Healthy group
(experiment 1)
0.9975 ± 0.005 0.9470 ± 0.059 0.9980 ± 0.005 0.9615 ± 0.046
Patients—placebo session
(experiment 2)
0.9968 ± 0.006 0.9447 ± 0.047 0.9958 ± 0.08 0.9547 ± 0.05
Patients—nalmefene session
(experiment 2)
0.9937 ± 0.013 0.9274 ± 0.073 0.9916 ± 0.018 0.9305 ± 0.082
FIGURE 2 | Behavioral measures (A: sensitivity index, B: reaction times) obtained in experiment 1. Bars represent mean; error bars depict standard errors. Reaction 
times were calculated for Go responses only.
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risk of consuming alcohol (European Medicines Agency, 2013). 
We verified that none of the patients took nalmefene or our 
vitamin D3 product earlier. Given that nalmefene reaches its 
peak plasma concentration in 1.5 h following oral intake, pills 
were administered ~1 h before the start of preparation for data 
collection. In order to control for potential learning effects in the 
Go/NoGo procedure, 50% of the participants received nalmefene 
first. On average, 39.7 h has passed between the repeated times 
of testing (min. 20 h, max. 149 h). We note that patients reported 
side effects after receiving nalmefene only. These were always of 
mild-to-moderate intensity: fatigue (N = 3), dejection (N = 2), 
dizziness (N = 2), nausea (N = 1), headache (N = 1), and dry 
mouth (N = 1). The Go/NoGo task was identical to that of 
experiment 1.
EEG Recording and Analysis
We used a 32-channel Nicolet Bravo Multimodal EEG System 
(EMS Co, Korneuburg, Austria) for recording neural activity in 
experiment 2 because the EEG system used in the first experiment 
was not available anymore. Sampling rate was set to 1,024 Hz; 
no frequency filters were used during data collection. Ag/AgCl 
electrodes were attached to an elastic EEG cap, with electrodes 
positioned in accordance with the International 10-20 System 
(Jasper, 1958). Electrodes were placed at scalp sites Fp1, Fp2, F3, 
F4, F7, F8, Fz, FC1, FC2, FC5, FC6, C3, C4, Cz, T7, T8, CP1, 
CP2, CP5, CP6, P3, P4, P7, P8, Pz, O1, O2, Oz, TP9, and TP10. 
Electrode AFz was used as reference, and electrode Fpz served 
as ground. The procedure of the data analysis was the same as 
described in experiment 1.
Statistical Analysis
As for behavioral data collected in experiment 1, the assumption 
of normality was violated for all three measures (Kolmogorov–
Smirnov test with Lilliefors correction, accuracy: p < 0.001; d′: 
p = 0.007; RT: p = 0.036). The nonparametric Friedman test was 
used to assess if there was a significant variation across treatment 
conditions and trial types. Follow-up pairwise comparisons were 
performed with Wilcoxon signed-rank tests, using Bonferroni-
adjusted alpha levels of 0.004 (accuracy) or 0.0125 (d′ and RT).
Results
Behavioral Measures
There was a significant variability in response accuracies across 
the four trial types in the two treatment sessions [χ2(7) = 92.42; 
p < 0.001, Table 2]. Pairwise comparisons indicated no effect of 
prime (Z > −1.42, p > 0.156) or treatment (Z > −1.89, p > 0.058) 
but significantly better accuracies in Go relative to NoGo trials 
(nalmefene + alcoholic prime: Z = −3.73, p < 0.001; nalmefene + 
nonalcoholic prime: Z = −3.24, p = 0.001; placebo + alcoholic 
prime: Z = −3.83, p < 0.001; placebo + nonalcoholic prime: 
Z = −3.64, p < 0.001).
Although we also found a significant effect for d′ [χ2(3)  = 
8.71; p = 0.033], follow-up pairwise comparisons did not 
reveal significant effects at our corrected alpha level (Z > −2.06, 
p  > 0.038). We note, however, that the sensitivity index was 
numerically smaller following nalmefene treatment for both 
prime types (Figure 4A).
With respect to RTs, we found significant variability 
across experimental conditions [χ2(3) = 8.63; p = 0.035], with 
significant differences between trials with alcoholic versus 
nonalcoholic primes under placebo treatment only (nalmefene: 
Z = −1.03, p = 0.304; placebo: Z = −3.58, p < 0.001; Figure 
4B). Treatment effects were not significant for either prime 
type (alcoholic: Z = −0.17, p = 0.862; nonalcoholic: Z = −0.34, 
p = 0.732). In order to avoid the fallacy of interpreting the 
difference between statistically significant and nonsignificant 
effects as “significant” (Gelman and Stern, 2006), we calculated 
nonalcoholic–alcoholic RT differences for each patient and 
performed an additional Wilcoxon signed-rank test to assess 
if the effect of nalmefene on reducing alcoholic cue-induced 
response invigoration was statistically meaningful. Indeed, we 
found significant differences between data from the placebo 
and the nalmefene sessions (Z = −2.20, p = 0.028; Figure 4C), 
FIGURE 3 | Occipital event-related potentials evoked by alcoholic and nonalcoholic primes (A) and frontal event-related potentials evoked by Go and NoGo targets in 
the context of alcoholic and nonalcoholic primes (B) in experiment 1. Stars depict significant (p < 0.05) differences between amplitudes obtained in different conditions.
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indicating that prime type was not influencing the speed of 
responding after active treatment.
Event-Related Potentials
Occipital P1, N1, and P2 Amplitudes
For the P1 and N1 amplitudes, we found no significant main effects 
or interactions (Figure 5A, Table 3). Similar to the effect observed 
in experiment 1, P2 amplitudes were sensitive to prime type, with 
smaller P2 amplitudes for alcoholic cues, but importantly, this 
effect was not modified by treatment type (Table 3).
Frontal N2 and P3 Amplitudes
Grand averaged frontal waveforms are presented in Figure 5B, 
with the corresponding statistical results shown in Table 4. For 
N2 amplitudes, no significant main effects or interactions were 
found. For the P3 component, repeated-measures ANOVA 
revealed larger P3 amplitudes for NoGo stimuli, but again, this 
component was insensitive to the administration of nalmefene or 
to the type of priming (Table 4).
DISCUSSION
In the current study, we aimed to investigate whether nalmefene 
influences the behavioral and neurophysiological correlates 
of appetitive cue processing, conflict detection, and response 
inhibition in AUD. A modified Go/NoGo paradigm was used, 
and ERPs were analyzed above occipital and frontal brain regions 
to assess the effect of treatment, alcoholic cues, and NoGo stimuli 
on cortical mechanisms of visual processing and executive 
FIGURE 4 | Behavioral measures (A: sensitivity index, B: reaction times, C: reaction time differences for nonalcoholic–alcoholic primes) obtained for experiment 2. 
Bars represent mean; error bars depict standard errors. Reaction times were calculated for Go responses only. Stars depict significant (p < 0.05) disparities between 
reaction times and differences of reaction times obtained in different priming and grouping conditions.
FIGURE 5 | Occipital event-related potentials evoked by alcoholic and nonalcoholic primes (A) and frontal event-related potentials evoked by Go and NoGo targets in 
the context of alcoholic and nonalcoholic primes (B) in experiment 2. Stars depict significant (p < 0.05) differences between amplitudes obtained in different conditions.
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control. Below, we shall discuss our results, starting with the 
behavioral effects of nalmefene.
Nalmefene Mildly Reduces Response 
Vigor to Alcoholic Cues in Patients  
With AUD
With respect to our behavioral results, rarely occurring NoGo 
stimuli were associated with higher rates of erroneous responses 
relative to Go stimuli in both experiments, but this effect was 
not influenced by nalmefene in AUD patients, and neither did 
we found nalmefene versus placebo differences in terms of 
the sensory index (d′). Although we did not directly compare 
behavioral measures from our healthy group to patient data 
from the placebo session (for reasons discussed below, under 
“Limitations”), the performance of both groups was strikingly 
similar, with near-ceiling effects (Table 2). Comparable 
behavioral performance on Go/NoGo tasks in patients with AUD 
relative to healthy controls has been commonly reported in the 
literature (Luijten et al., 2014), but it is puzzling why we did not 
detect more false alarms and lower d′ values in alcohol-primed 
trials in placebo-treated patients. Impaired executive control in 
the context of alcohol cues has been well documented in social 
drinkers (Martinovic et al., 2014; Dyke and Fillmore, 2015), but 
in our study, such effects might have been masked by the very 
high accuracy rates in the patient group. Perhaps, using shorter 
(< 1,000 ms) time windows for responding would have been 
more appropriate for uncovering between-treatment differences 
in accuracy or sensitivity index measures.
The main finding of our study is that primes depicting 
pictures of alcoholic drinks were followed by significantly 
faster response times in patients receiving placebo, while 
such an effect was absent in patients receiving nalmefene and 
in healthy participants. Despite this statistically significant 
effect, it is important to highlight that the magnitude of the 
RT difference between the two treatment conditions was very 
small (in the range of few milliseconds; Figure 4C), rendering 
the current finding behaviorally and clinically less pronounced. 
Although we consider the RT effect to be very small in our 
study, it is primarily due to the weak influence of alcoholic cues 
on response times under placebo, and thus, our finding does 
not preclude the possibility that nalmefene could have exerted 
more robust effects under different circumstances. Namely, it 
is possible that either by recruiting a patient group that is more 
sensitive to our alcoholic cues (e.g., by investigating nonabstinent 
patients) or by modifying our paradigm to be more sensitive to 
detect cue-induced response invigoration in our patient sample 
(e.g., using a shorter time window for responding), we would 
have observed nalmefene versus placebo differences that are 
behaviorally also meaningful. The fact that even alcoholic cues 
induced substantially longer responses in AUD patients than in 
healthy participants (Figures 2B vs. 4B) points toward a general 
psychomotor slowing in AUD, which is well-known in this 
disorder (De Wilde et al., 2007; Lawrence et al., 2009).
Another interesting aspect of our result is that nalmefene did 
not prolong reaction times in general, which is in contrast to the 
finding reported by Quelch et al. (2017). While the reason for 
the absence of an overall RT prolongation after active treatment 
in our study is unclear, we speculate that it might be related 
to differences in time constraints. In particular, patients were 
provided with plenty of time (1,000 ms) to respond to targets in 
the current paradigm, whereas they had to react within a much 
shorter time window (150–300 ms) in the study by Quelch et al. 
(2017). Taken together, our result indicates that alcoholic stimuli 
might facilitate approach tendencies in AUD, an effect that is 
likely to be governed by learned Pavlovian-type associations 
and has been associated with the dopaminergic system (Everitt 
and Robbins, 2005; Garbusow et al., 2014). Indeed, fast reaction 
times (a measure of response vigor) were linked to phasic 
dopamine signals (Satoh et al., 2003), and considering that 
appetitive cues in our paradigm might have enhanced the firing 
of midbrain dopaminergic neurons in patients with placebo, our 
finding of faster responses upon alcoholic primes fits well into 
the incentive-sensitization theory of addiction (Robinson and 
Berridge, 2003). The fact that such response invigoration for 
alcoholic primes disappeared after nalmefene intake indicates 
that nalmefene might have inhibited subcortical dopaminergic 
transmission. Although we argue that this molecular effect of 
TABLE 3 | Statistical results (main effects and interactions) of ANOVA 
performed for the occipital P1, N1 and P2 components in Experiment 2.
ERP Main effects and 
interactions
df F p ηp2
P1 MEDICATION 1,18 1.094 0.310 0.057
PRIME 1,18 0.044 0.836 0.002
MEDICATION x PRIME 1,18 0.680 0.420 0.036
N1 MEDICATION 1,18 0.001 0.973 0.000
PRIME 1,18 0.912 0.352 0.048
MEDICATION x PRIME 1,18 0.225 0.641 0.012
P2 MEDICATION 1,18 0.044 0.836 0.002
PRIME 1,18 15.476 0.001* 0.462
MEDICATION x PRIME 1,18 0.069 0.796 0.004
*p < 0.01; ERP, Event Related Potentials.
TABLE 4 | Statistical results (main effects and interactions) of ANOVA 
performed for the frontal N2 and P3 components in experiment 2.
ERP Main effects and 
interactions
df F p ηp2
N2 MEDICATION 1,18 0.095 0.761 0.005
PRIME 1,18 0.035 0.854 0.002
TARGET 1,18 0.304 0.588 0.017
MEDICATION x PRIME 1,18 0.521 0.480 0.028
MEDICATION x TARGET 1,18 0.628 0.438 0.034
PRIME x TARGET 1,18 0.093 0.764 0.005
MEDICATION x PRIME x 
TARGET
1,18 1.467 0.241 0.075
P3 MEDICATION 1,18 0.632 0.437 0.034
PRIME 1,18 0.143 0.710 0.008
TARGET 1,18 19.452  < 0.001* 0.519
MEDICATION x PRIME 1,18 0.000 0.985 0.000
MEDICATION x TARGET 1,18 0.000 0.985 0.000
PRIME x TARGET 1,18 1.387 0.254 0.072
MEDICATION x PRIME x 
TARGET
1,18 0.016 0.900 0.001
*p < 0.01; ERP, Event Related Potentials.
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nalmefene is related to modulations of the Pavlovian learning 
system in patients, we note that our Go/NoGo task was 
substantially different from PIT tasks that have been successfully 
used to elucidate the nature of Pavlovian response biases in AUD 
(Garbusow et al., 2014; Schad et al., 2019). In particular, our task 
did not involve a conditioning phase or instrumental learning 
whatsoever, and therefore, it might be sensitive to psychological 
processes and neural circuits distinct from those associated with 
PIT tasks.
Nalmefene Does not Influence Neural 
Responses to Alcohol Cues or ERPs 
Reflecting Executive Control
With respect to prime-induced early visual ERPs, no effects 
were found for the posterior P1 and N1 components, 
suggesting that these ERPs were not influenced by prime 
type (alcoholic vs. nonalcoholic) or treatment (nalmefene vs. 
placebo). On the other hand, the P2 component was significantly 
larger for nonalcoholic relative to alcoholic primes in both 
experiments. The posterior P2 not only has been implicated in 
perceptual grouping and attention (Han et al., 2005; Straube and 
Fahle, 2009; Schendan and Lucia, 2010), but it is also sensitive 
to emotional valence of visual images, being larger in amplitude 
for unpleasant stimuli (Carretié et al., 2001; Olofsson and Polich, 
2007). Thus, there is no clear functional description of the visual 
P2, and given that our nonalcoholic primes depicted popular 
drinks commonly associated with positive (rather than negative) 
feelings, our results regarding the P2 are difficult to interpret. 
Still, it is clear that nalmefene did not modulate this component, 
and therefore, we can conclude that all three visual ERPs were 
insensitive to our pharmacological intervention. This was a 
surprising result since these posterior components reflect not 
only bottom–up sensory processing of visual inputs but are also 
sensitive to top–down influences such as the effects of attention, 
expectation, and emotional responses (Carretié et al., 2001; 
Han et al., 2005; Straube and Fahle, 2009; Schendan and Lucia, 
2010). Thus, we hypothesized that, through direct and indirect 
effects of nalmefene on opioid and dopaminergic signaling, this 
drug would alter the sensitivity of visual ERPs to appetitive and 
more salient cues depicting alcoholic drinks. The fact that such 
an effect was absent from our EEG data despite observing cue-
induced response invigoration on the behavioral level points 
toward subcortical pharmacological effects of nalmefene that 
rendered early cortical analysis of visual stimuli intact.
We also analyzed the target-locked frontal N2 and P3 
components that reflect conflict monitoring and inhibitory 
processes (Huster et al., 2011; Luijten et al., 2014), and therefore, 
they can be regarded as neural indices of efficient executive 
control in our task. We found that only healthy participants 
showed larger NoGo-associated N2 amplitudes, pointing towards 
impaired conflict detection for NoGo trials in the patient group. 
The magnitude of NoGo versus Go amplitude differences for the 
N2 component has been previously associated with the degree 
of alcohol avoidance in a subclinical sample, such that larger 
NoGo-related N2 amplitudes were found in individuals with 
high avoidance from alcohol (Kreusch et al., 2014). Although we 
did not collect data on the predisposition to refrain from alcohol 
consumption, our result point towards low alcohol avoidance in 
our patient group, which is not surprising given that they were 
all abstinent for <2 months at the time of data collection. Our 
finding on the N2 also aligns well with that reported by Pandey 
and colleagues (Pandey et al., 2012) and strengthen views on 
impaired executive control and frontal lobe (in particular, 
dACC) dysfunction in AUD (Moselhy et al., 2001; Ratti et al., 
2002; Kamarajan et al., 2005; Pandey et al., 2012).
In line with the vast amount of literature on the ERP correlates 
of response inhibition (Huster et al., 2011; Luijten et al., 2014; 
Hong et al., 2017), we observed larger central P3 amplitudes 
for NoGo stimuli in both experiments and for both treatment 
sessions in patients. These findings indicate that cortical processes 
associated with inhibiting automatic response tendencies were 
intact in our patients. Previous studies focusing on the P3 in 
tasks requiring inhibitory control in AUD yielded mixed results, 
reporting either reduced or intact P3 amplitudes in patients 
(Luijten et al., 2014). As for the absence of the NoGo-related N2 
effect, the large NoGo versus Go P3 amplitude difference in our 
patients might be related to their low alcohol avoidance (Kreusch 
et al., 2014), but this should have been assessed explicitly in the 
current study. Given that the P3 is the last prominent ERP in the 
cascade of neural events associated with response inhibition, and 
it has been localized to cortical regions such as the supplementary 
motor area (Huster et al., 2010; Huster et al., 2011), we can 
expect that its amplitude is informative of the success of motor 
inhibition. Indeed, in parallel to the significant Go versus NoGo 
P3 amplitude difference in our patient group that was insensitive 
to nalmefene, we did not find differences in response accuracy 
or the sensitivity index after nalmefene versus placebo intake. 
Overall, we conclude that deficits in conflict monitoring (N2 
component) and intact neural correlates of motor inhibition (P3 
component) in AUD are (I) not modified by alcohol cues and 
(II) are not influenced by nalmefene. Thus, it is not likely that 
any of these ERPs are related to the beneficial behavioral effect of 
nalmefene on alcohol-primed RTs.
To our knowledge, the study by Quelch and colleagues 
(Quelch et al., 2017) was the only study that investigated 
the neural effects of nalmefene in human participants using 
neuroimaging methods. Although the authors found reduced 
blood-oxygen-level-dependent responses following nalmefene 
administration in the striatum and brainstem but not in any 
cortical area, regions in the frontal cortex (such as the dACC) 
that are interconnected with these dopaminergic structures 
(Di Martino et al., 2008; Furman et al., 2011) could have been 
theoretically influenced by neurochemical alterations caused 
by the drug. Based on this, we hypothesized that the effect of 
nalmefene would manifest in enhanced N2/P3 amplitudes in a 
task that relies on conflict monitoring and response inhibition. 
However, our null results in this regard support the functional 
magnetic resonance imaging findings of Quelch and colleagues 
(Quelch et al., 2017) in that nalmefene might primarily act via 
subcortical mechanisms in AUD and does not influence cortical 
activity arising from multiple sources in the frontal lobe that have 
been implicated in executive control. This conclusion coincides 
with nalmefene’s clinical indications: this agent is primarily used 
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as an as-needed, harm-reducing treatment option rather than as 
therapy for reaching long-term abstinence.
Limitations
Although participants from experiment 1 did not differ in gender 
distribution, age, and education level from patients enrolled in 
experiment 2 [gender: χ2(1) = 0.009, p = 0.925; age: t(37) = 1.695, 
p = 0.098; education: U = 166, Z = −0.76, p = 0.447], the main 
limitation of our study is that we could not directly compare data 
from healthy participants to those collected in patients receiving 
placebo for three reasons. First, our healthy participants were not 
blind to the treatment, as they were informed about receiving 
placebo. Second, the crossover design of experiment 2 might have 
induced learning effects for the placebo data (i.e., half of patients 
started with the nalmefene session), making the control versus 
patient comparison problematic. Third, we had to use a different 
EEG device in experiment 2, which might have introduced 
latent effects to the ERPs. Therefore, we made only qualitative 
between-group comparisons for two relevant measures (longer 
RTs in patients, the absence of the Go vs. NoGo effect for the N2 
component in patients), and these should be treated with caution.
Another limitation is that, due to the strict ethical restrictions 
about the administration of nalmefene to healthy adults, we 
could not investigate the behavioral and neural effects of this 
agent in individuals without AUD. Finally, our patient group 
was heterogeneous in terms of the duration of abstinence (i.e., 
between 2 weeks and 2 months), and given that the patients at 
different stages of abstinence from substance abuse show distinct 
patterns of cognitive impairment (Fernández-Serrano et al., 
2011), it is possible that different outcomes could have been 
observed in a more homogenous sample.
Conclusions
This work is one among the few studies (Quelch et al., 2017) 
designed with the aim to fulfil the informational gap in 
understanding how nalmefene influences cortical mechanisms 
associated with executive control and the processing of alcoholic 
cues. It seems that this agent affects approach behavior when 
patients with AUD are primed with pictures depicting alcoholic 
drinks, but this effect was very mild in our study, with limited 
behavioral relevance. Moreover, we found that nalmefene does 
not influence ERP signatures of executive control or visual 
processing. These results suggest that nalmefene modulates 
response invigoration presumably related to subcortical 
dopaminergic transmission, as it did not influence cortical 
processing in our task. Future studies could design experimental 
paradigms that enable exploring the mechanisms of nalmefene’s 
effect on incentive salience more precisely.
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